, « Physiologie rénale, vol.99, issue.3, pp.237-249, 2012.
, Physiologie du rein et bases physiopathologiques des maladies rénales, vol.2013, pp.25-37, 2013.
, Rev. Prat, vol.60, pp.1431-1442, 2010.
Christophe Legendre, L'insuffisance rénale chronique : prévention et traitement, 2011. ,
Age and gender-specific reference values of estimated GFR in Caucasians, Nijmegen Biomed. Study, pp.632-637, 2007. ,
« Estimation et caractérisation de l'insuffisance rénale chronique en France, Ann. Cardiol. Angéiologie, vol.61, issue.4, pp.239-244 ,
, Épidémiologie des maladies rénales chroniques, vol.2, pp.139-157, 2005.
, Incidence de l'insuffisance rénale chronique en population générale, étude EPIRAN », Néphrologie Thérapeutique, vol.5, pp.250-255, 2009.
, Chronic Kidney Dis. Aware, 1999.
, , vol.36, pp.1811-1821, 2007.
« Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte Treatment strategies to slow the progression of chronic renal failure in adults, Néphrologie Thérapeutique, vol.1, pp.84-89, 2005. ,
suivi biologique de l'insuffisance rénale chronique et prise en charge de l'insuffisance rénale chronique terminale, Rev. Francoph. Lab, vol.2013, pp.59-73, 2013. ,
« Insuffisance rénale : stratégie diagnostique, J. Radiol, vol.92, issue.4, pp.299-307, 2011. ,
« Insuffisance rénale chronique et maladie cardiovasculaire, Ann. Cardiol. Angéiologie, vol.58, issue.1, pp.40-52, 2009. ,
« Altération modérée de la fonction rénale et risque cardiovasculaire, Rev. Médecine Interne, vol.30, issue.7, pp.585-591, 2009. ,
Dr Fitsum Guebre-Egziabher, « Maladie rénale chronique, Concours Méd, vol.135, issue.3, p.199, 2013. ,
« Moyens thérapeutiques pour ralentir la progression de l'insuffisance rénale chronique chez l'adulte Treatment strategies to slow the progression of chronic renal failure in adults, Néphrologie Thérapeutique, vol.1, pp.84-89, 2005. ,
, Équilibre phosphocalcique : régulation et explorations », Néphrologie Thérapeutique, vol.7, pp.118-138, 2011.
« Troubles minéraux et osseux de la maladie rénale chronique (TMO-MRC), Rev. Francoph. Lab, vol.2013, pp.29-43, 2013. ,
, Hyperphosphatemia of chronic kidney disease, vol.74, pp.148-157, 2008.
Kuro-o, « Role of Klotho in Aging, Phosphate Metabolism, and CKD », Am. J. Kidney Dis, vol.58, issue.1, pp.127-134, 2011. ,
,
« Physiopathologie de l'hyperparathyroïdie secondaire de l'insuffisance rénale chronique ,
Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study, J Clin Endocrinol Metab, 2016. ,
, Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options, vol.6, pp.913-921, 2011.
, Insuffisance rénale et métabolisme du calcium et du phosphate, vol.79, pp.258-261, 2012.
, Rev. Francoph. Lab, vol.2012, pp.33-42, 2012.
Adynamic bone in patients with chronic kidney disease, Kidney Int, vol.73, pp.1345-1354, 2008. ,
« Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, vol.69, issue.11, pp.1945-1953, 2006. ,
, Cellules osseuses et remodelage osseux. », 1993.
« Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study, Kidney Int, vol.70, pp.1358-1366, 2006. ,
regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure, Kidney Int, vol.58, pp.1440-1449, 2000. ,
, The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease, vol.24, pp.3120-3125, 2009.
, Bone histology in incipient and advanced renal failure, vol.9, pp.355-362, 1976.
« Repression of osteocyte Wnt/?-catenin signaling is an early event in the progression of renal osteodystrophy, J. Bone Miner. Res, vol.27, issue.8, pp.1757-1772 ,
, Le remodelage osseux et ses implications thérapeutiques dans l'ostéoporose: mise au point », Rev. Marocaine Rhumatol, p.21, 2012.
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo, Blood, vol.109, issue.5, pp.2106-2111, 2007. ,
Aplastic osteodystrophy without aluminium: The role of suppressed parathyroid function, Kidney Int, vol.44, pp.860-866, 1993. ,
« Ostéodystrophie rénale (1); diagnostic invasif et non invasif des variétés histopathologiques, vol.21, pp.229-237, 2000. ,
« Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. », J Clin Endocrinol Metab, vol.73, issue.3, pp.516-540, 1991. ,
, Désordres du métabolisme phospho-calcique et complications ostéoarticulaires, 2007.
, The natural course of dialysis osteomalacia, vol.18, pp.74-79, 1986.
, Osteodystrophie rénale. Aspects clinicoradiologiques, physiopathologie et traitement. », Encycl. Méd.-Chir, vol.18, pp.1-16, 1994.
Aluminum intoxication from aluminum containing phosphate binders in children with azotemia not undergoing dialysis, N Engl JM, vol.310, pp.1079-83, 1984. ,
Experimental evidence for strontium to play a role in the development of dialysis related osteomalacia. », J Am Soc Nephrol, vol.8, p.555, 1997. ,
« Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?, Kidney Int, vol.55, issue.6, pp.2169-2177, 1999. ,
, « 1?OH vitamin D3 increases plasma aluminum in hemodialyzed patients taking AlOH3, vol.33, pp.175-177, 1988.
L'ostéoporose, mieux la comprendre pour mieux la traiter, 2009. ,
Bente Langdahl, et Klaus Olgaard, « Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure, Kidney Int, vol.56, pp.1084-1093, 1999. ,
« Increased risk of hip fracture among patients with end-stage renal disease, Kidney Int, vol.58, issue.1, pp.396-399, 2000. ,
« Risk factors for hip fracture among patients with end-stage renal disease, Kidney Int, vol.58, issue.5, pp.2200-2205, 2000. ,
, Aluminium toxicity in patients undergoing dialysis: radiographic findings and prediction of bone biopsy results, vol.164, pp.399-403, 1987.
, Nephrol. Dial. Transplant, vol.11, pp.74-79, 1996.
Haese PC, « Aluminium transferrin but not Al citrate uptake by the parathyroid gland may contribute to the development of hypoparathyroidism associated with adynamic bone disease, J Am Soc Nephrol, vol.6, p.940, 1995. ,
« Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay, J Clin Endocrinol Metab, vol.65, issue.3, pp.407-414, 1987. ,
« Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity », Am J Kidney Dis, vol.26, issue.5, pp.836-880, 1995. ,
, Recommandations KDIGO de bonnes pratiques cliniques pour le diagnostic, l'évaluation, la prévention et le traitement des troubles minéraux et osseux associés aux maladies rénales chroniques
« Ostéodystrophie rénale (1); diagnostic invasif et non invasif des variétés histopathologiques, vol.21, pp.229-237, 2000. ,
, Periosteal New Bone Formation, vol.110, 1974.
, , pp.96-128, 1997.
« Mineralized bone loss at different sites in dialysis patients: implications for prevention. », J. Am. Soc. Nephrol, vol.9, issue.7, pp.1225-1233, 1998. ,
Adynamic bone disease : Pathogenesis, diagnosis and clinical relevance, Curr Opin Nephrol Hypertens, issue.6, pp.356-61, 1997. ,
, Kidney Int, vol.55, pp.299-307, 1999.
« Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability, Nephrol. Dial. Transplant, vol.25, issue.11, pp.3707-3717, 2010. ,
,
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, vol.310, pp.358-363, 1995. ,
« Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure, Nephrol Dial Transpl, vol.10, pp.2228-2262, 1995. ,
« Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure, Nephrol Dial Transpl, vol.19, pp.870-876, 2004. ,
, Nephrologie, vol.23, issue.4, pp.151-164, 2002.
« Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N. Engl. J. Med, vol.350, pp.1516-1525, 2004. ,
« Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity, Clin Nephrol, vol.76, pp.233-276, 2011. ,
, Place des nouveaux traitements de l'ostéodystrophie rénale : dérivés 1?hydroxylés de la vitamine D « non hypercalcémiants », complexants non calciques, non magnésiens et non aluminiques des phosphates, vol.21, pp.9-32, 2006.
« Comparison of 1?-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization, Kidney Int, vol.15, issue.2, pp.196-204, 1979. ,
« Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum, Nephron, vol.56, pp.93-101, 1989. ,
, Reflex. Rhumatol, vol.16, pp.11-15, 2012.
Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis, Kidney Int, vol.63, pp.88-90, 2003. ,
« Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis, Kidney Int, vol.63, issue.6, pp.2269-2274, 2003. ,
et for the MORE Investigators, « The Effect of Raloxifene Treatment in Postmenopausal Women with CKD, J. Am. Soc. Nephrol, vol.19, issue.7, pp.1430-1438, 2008. ,
« Targeting the Wnt/?-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton, Endocrinology, vol.148, issue.6, pp.2635-2643, 2007. ,
« Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways, J. Biol. Chem, vol.285, pp.41614-41626 ,
Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model, J. Am. Soc. Nephrol, vol.15, issue.2, pp.359-369, 2004. ,
« Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*, J. Bone Miner. Res, vol.24, issue.4, pp.578-588, 2009. ,
« Romosozumab Treatment in Postmenopausal Women with Osteoporosis, N. Engl. J. Med, vol.375, pp.1532-1543, 2016. ,
« Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH<sub>1-34</sub>): A Pilot Study, Kidney Blood Press. Res, vol.33, issue.3, pp.221-226, 2010. ,
, Profil d' expression ostéocytaire et troubles de la minéralisation et du remodelage osseux dans l'ostéodystrophie rénale, 2017.
Bicarbonate de sodium pour ralentir la progression de la maladie rénale chronique, Rev. Médicale Suisse, pp.478-82, 2011. ,
Potential renal acid load of foods and its influence on urine pH, J Am Diet Assoc, vol.95, pp.791-797, 1995. ,
, « Les tomates préviennent-elles l'ostéoporose? », Endocrinologie, vol.5, 2005.
, J Cell Biochem, vol.56, issue.3, pp.367-73, 1994.
« Stimulation of osteoclastic bone resorption by hydrogen peroxide, Biochem. Biophys. Res. Commun, vol.183, issue.3, pp.1153-1158, 1992. ,
, Oxygen derived free radicals in osteoclasts: The specificity and location of the nitroblue tetrazolium reaction, vol.11, pp.115-119, 1990.
, Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants, vol.418, pp.91-97, 1997.
, Principes de l'alimentation santé
The importance of meeting calcium needs with foods, J Am Coll Nutr, vol.20, pp.85-165, 2001. ,
« Vitamin D Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials », Clin. J. Am. Soc. Nephrol, vol.6, issue.1, pp.50-62, 2011. ,
« Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation, Nephrol. Dial. Transplant, vol.24, pp.3799-3805, 2009. ,
, Vitamine D: actualité et recommandations
« Human plasma transport of vitamin D after its endogenous synthesis. », J. Clin. Invest, vol.91, issue.6, p.2552, 1993. ,
, La Biopsie osseuse à visée histomorphométrique, 2015.
« Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med, vol.351, issue.13, pp.1296-1305, 2004. ,